REGN

Business Context and Reporting Period

Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing pharmaceutical products for serious medical conditions. The company has no approved products for sale and has incurred cumulative losses since inception. Its strategy relies on proprietary technology platforms (VelocImmune, VelociGene) and strategic collaborations with major pharmaceutical partners, primarily sanofi-aventis and Bayer HealthCare.

Key Financial Metrics

Note: The $200 million convertible debt matured in October 2008 and was reclassified as current in 2007.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue nearly doubled from $63.4 million in 2006 to $125.0 million in 2007. This was driven by a significant increase in contract research and development revenue ($96.6 million vs. $51.1 million) and the addition of technology licensing revenue ($28.4 million), which was non-existent in 2006.
• Expense Increase: Operating expenses rose to $239.5 million from $171.1 million. Research and development expenses increased by $64.5 million, primarily due to expanded clinical programs (VEGF Trap-Eye, ARCALYST), higher headcount (average 627 vs. 573), and increased stock-based compensation ($28.0 million vs. $18.4 million).
• Liquidity Improvement: Cash and marketable securities increased by approximately $323 million to $846.3 million. This was fueled by a $312 million equity investment from sanofi-aventis, an $85 million upfront payment from a new antibody collaboration, and $40 million in licensing fees from AstraZeneca and Astellas.
• Segment Change: The company ceased reporting a "Contract Manufacturing" segment in 2007 following the expiration of its agreement with Merck in October 2006. Operations are now consolidated into a single Research and Development segment.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Product Pipeline: The company is advancing four clinical programs: ARCALYST (inflammatory diseases), aflibercept (oncology), VEGF Trap-Eye (eye diseases), and REGN88 (rheumatoid arthritis). A BLA for ARCALYST in CAPS was under FDA priority review with a decision expected in February 2008.
• Collaborations: In November 2007, Regeneron entered a global strategic collaboration with sanofi-aventis to discover and develop fully human monoclonal antibodies, receiving an $85 million upfront payment and up to $475 million in research funding through 2012.
• Financial Outlook: Management expects to incur substantial losses over the next several years. They believe existing capital resources, including collaboration funding, will meet operating needs through at least 2012.

Risks and Contingencies

• Debt Maturity: $200 million in convertible senior subordinated notes mature in October 2008. If the stock price is below the conversion price ($30.25) at maturity, the company must repay the principal or refinance.
• Regulatory Approval: There is no assurance that product candidates will receive FDA approval. The efficacy data for ARCALYST in CAPS may be deemed inadequate by the FDA.
• Competition: Significant competition exists in oncology (e.g., Genentech's Avastin) and eye diseases (e.g., Genentech's Lucentis), which could impact commercial success even if approval is obtained.
• Intellectual Property: The company faces potential patent disputes, including a disagreement with Cellectis regarding the scope of a license for VelocImmune technology.

Investor Verification Checklist

• Debt Refinancing: Verify the company's ability to refinance or convert the $200 million debt maturing in October 2008.
• ARCALYST Approval: Monitor the FDA decision on the Biologics License Application (BLA) for ARCALYST in CAPS, expected in early 2008.
• Collaboration Terms: Review the specific performance milestones and funding schedules within the new sanofi-aventis antibody collaboration and the Bayer HealthCare VEGF Trap-Eye agreement.
• Revenue Recognition: Examine the accounting treatment of upfront payments from collaborators (sanofi-aventis, Bayer, AstraZeneca, Astellas) and the estimated performance periods used for revenue recognition.
• Investment Portfolio: Assess the credit quality of the company's marketable securities, noting the $5.9 million impairment charge taken in 2007 and the $14 million exposure to securities with deteriorating credit quality.